VYGR — Voyager Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1640266 ·
Last close
$2.68
Market Cap
$165.14M
52W High
$5.55
52W Low
$2.64
ADV30
477,003
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,165,000 | — | -26,392,000 | -24,473,000 | 197,753,000 | 35,769,000 | 43,376,000 |
| Mar 2026 | 2,593,000 | — | -30,270,000 | -27,937,000 | 219,325,000 | 43,314,000 | 45,656,000 |
| Dec 2025 | 15,336,000 | — | -29,932,000 | -27,426,000 | 252,281,000 | 65,300,000 | 56,200,000 |
| Sep 2025 | 13,365,000 | — | -30,594,000 | -27,892,000 | 288,311,000 | 45,125,000 | 68,486,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-120,572,000
Investing CF
$105,804,000
Financing CF
$6,269,000
CapEx
$-1,952,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.81
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-498,315,000
Inventory
—
Receivables
$3,154,000
ST Investments
$80,569,000
EBIT TTM
$-117,188,000
Pretax Income TTM
$-107,602,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$34,459,000
EBITDA
$-109,867,000
Free Cash Flow
$-77,310,000
Enterprise Value
$112,790,256
Total Cash
$116,338,000
Total Debt
$32,567,000
Shares Out
61,617,948
Trailing EPS
$-1.81
Book Value
$2.88
ROE
-54.1%
ROA
-27.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 40,374,000 | -131,844,000 | -119,721,000 | 252,281,000 | 56,200,000 | 196,081,000 | -132,467,000 |
| Dec 2024 | 80,001,000 | -83,287,000 | -65,002,000 | 393,050,000 | 93,290,000 | 299,760,000 | -15,310,000 |
| Dec 2023 | 250,008,000 | 122,014,000 | 132,330,000 | 351,281,000 | 114,961,000 | 236,320,000 | 77,919,000 |
| Dec 2022 | 40,907,000 | -50,837,000 | -46,408,000 | 159,356,000 | 100,336,000 | 59,020,000 | -12,509,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.28
Max Pain — expiry 2026-10-16
max pain strike: $3.00 · spot: $2.65 · call oi: 3,631 · put oi: 324
Expected Move to 2026-10-16:
±$0.62
(23.54%) —
implied range
$2.03 –
$3.28
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MOLN | MOLECULAR PARTNERS AG | $164.71M | $4.30 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $161.99M | $2.24 | — |
| DTIL | PRECISION BIOSCIENCES INC | $171.68M | $6.22 | — |
| CHRS | Coherus Oncology, Inc. | $174.59M | $1.13 | — |
| OTLK | Outlook Therapeutics, Inc. | $155.81M | $0.64 | — |
News headlines (Yahoo Finance, 1h cache)
Voyager to Present at Upcoming Investor Conferences
2026-09-01 12:00 · Yahoo
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 23:10 · Yahoo
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
2026-07-13 12:01 · Yahoo
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
2026-07-02 13:33 · Yahoo
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside
2026-06-30 16:34 · Yahoo
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
2026-06-29 12:01 · Yahoo
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
2026-06-11 20:01 · Yahoo
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
2026-06-01 12:00 · Yahoo
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
2026-05-20 12:35 · Yahoo
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
2026-05-13 10:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.